Results 91 to 100 of about 1,352 (137)

Molecular imaging supports the development of multispecific cancer antibodies [PDF]

Multispecific antibodies are engineered antibody derivatives that can bind to two or more distinct epitopes or antigens. Unlike mixtures of monospecific antibodies, the binding properties of multispecific antibodies enable two specific molecules to be ...
Brouwers, Adrienne H, de Groot, Derk Jan A, de Vries, Elisabeth G E, Lub-de Hooge, Marjolijn N, Pierik, Frank R, van Winkel, Claudia A J   +5 more
core   +1 more source

Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models

Breast Cancer Research
Background Immune-positron emission tomography (PET) imaging with tracers that target CD8 and granzyme B has shown promise in predicting the therapeutic response following immune checkpoint blockade (ICB) in immunologically “hot” tumors.
Yun Lu, Hailey A. Houson, Carlos A. Gallegos, Alessandro Mascioni, Fang Jia, Argin Aivazian, Patrick N. Song, Shannon E. Lynch, Tiara S. Napier, Ameer Mansur, Benjamin M. Larimer, Suzanne E. Lapi, Ariella B. Hanker, Anna G. Sorace   +13 more
doaj   +1 more source

Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer

Frontiers in Immunology
Small cell lung cancer (SCLC), accounting for 10–20% of lung cancers, remains one of the most aggressive neuroendocrine malignancies, with fewer than 7% of patients surviving beyond five years. While the addition of immune checkpoint inhibitors (ICIs) to
Kangkang Ji, Kangkang Ji, Lin Guo, Dianbao Zuo, Mingqian Feng, Xin Chen, Zhenggang Zhao, Jing Tang, Guoping Chen   +8 more
doaj   +1 more source

ISEV2025 Abstract Book

Journal of Extracellular Vesicles, Volume 14, Issue S1, October 2025.
wiley   +1 more source

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging [PDF]

, 2009
Lars R. Perk, Maria J. W. D. Vosjan, Gerard W. M. Visser, Marianne Budde, Paul Jurek, Garry E. Kiefer, Guus A. M. S. van Dongen, PJ Carter, GAMS Dongen van, AM Wu, TK Nayak, I Verel, E Dijkers, LR Perk, PKE Borjesson, WB Nagengast, I Verel, I Verel, A Brouwers, LR Perk, J Mendelsohn, AH Schrijvers, SR Rangan, MJ Welters, T Lindmo, CF Meares, LR Perk, HWAM Jong de, AM Loening, A Yokoyama, M Koizumi, S Pochon, WE Meijs, S Liu, FB Gog van, DL Kukis, MC Chakrabarti   +36 more
core   +1 more source

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical ⁸⁹Zr-immuno-PET. [PDF]

Eur J Nucl Med Mol Imaging, 2021
Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ.   +15 more
europepmc   +1 more source

Toward Optimized ⁸⁹Zr-Immuno-PET: Side-by-Side Comparison of [⁸⁹Zr]Zr-DFO-, [⁸⁹Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [⁸⁹Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? [PDF]

Pharmaceutics, 2022
Damerow H, Cheng X, von Kiedrowski V, Schirrmacher R, Wängler B, Fricker G, Wängler C.   +6 more
europepmc   +1 more source

Fully automated production of Zr-89 using IBA Nirta and Pinctada Systems [PDF]

, 2015
Few PET isotopes are suitable for antibody labelling since immunoPET requires that the PET isotope can be attached to the mAb with high in-vivo stability and the decay half-life of the isotope should match the pharmacokinetics of the mAb (Phelps 2004 ...
Panopoulos, H., Poniger, S., Scott, A., Tochon-Danguy, H.   +3 more
core   +1 more source

BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study [PDF]

, 2017

core   +1 more source

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients [PDF]

, 2014

core   +1 more source